We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > BioLexa

News List

Hoth Therapeutics' Enrollment and Dosing in Second Cohort in Phase 1b Human Trial for Atopic Dermatitis Under Way prnewswire
December 01, 2021
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce that enrollment...
Hoth Therapeutic Submits Ethics Approval Request for Atopic Dermatitis Trial americanpharmaceuticalreview
August 18, 2020
Hoth Therapeutics has submitted for ethics approval in Australia for its planned Clinical study of its therapeutic BioLexa for Atopic Dermatitis. The ethics submission was made to the Bellberry Human Research Ethics Committee in Australia.
Hoth Signs Contract Service Pacts for BioLexa contractpharma
June 19, 2019
Particle Sciences, Regis Technologies called on for upcoming toxicology and clinical trials.